Dr. Gibbs on Predicting Response to Treatment in Osteosarcoma

Video

C. Parker Gibbs Jr., MD, discusses the use of cell cycle checkpoint regulators to indicate response to treatment in osteosarcoma.

C. Parker Gibbs Jr., MD, Eugene L. Jewett professor of Orthopaedic Surgery, chief medical officer, University of Florida Health Shands Hospital, division chief, musculoskeletal oncology, University of Florida College of Medicine, discusses the use of cell cycle checkpoint regulators to indicate response to treatment in osteosarcoma.

Osteosarcoma is a highly malignant disease in children and adolescents. However, there are few prognostic markers that indicate how a patient is going to do after treatment with chemotherapy and surgery, explains Gibbs. Currently, a patient’s prognosis is based on tumor characteristics following chemotherapy and surgical resection, says Gibbs.

Currently, there is no way to predict a patient’s likelihood of response to chemotherapy or risk of metastatic disease prior to treatment. However, a study looking at 2 cell cycle checkpoint inhibitors, P16 and P21, have shown promise for indicating aggressive disease biology. When these 2 biologic markers were evaluated in over 100 osteosarcoma specimens, investigators found an association between their expression, metastatic disease, and overall survival in children and adolescents. Gibbs believes this is a major advance because it could allow patients to be stratified prior to treatment and help personalize treatment.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,